JNJ · Johnson & Johnson
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-20 | Broadhurst Vanessa |
EVP, Global Corp Affairs |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades at prices ranging from $251.09 to $251.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
23,054 |
| 2026-07-20 | Broadhurst Vanessa |
EVP, Global Corp Affairs |
Convert↑
|
Common Stock
|
11,925 |
| 2026-07-20 | Broadhurst Vanessa |
EVP, Global Corp Affairs |
Convert↑
|
Common Stock
|
11,129 |
| 2026-07-20 | Broadhurst Vanessa |
EVP, Global Corp Affairs |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
11,129 |
| 2026-07-20 | Broadhurst Vanessa |
EVP, Global Corp Affairs |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
11,925 |
| 2026-06-11 | Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades at prices ranging from $240.14 to $240.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
10,000 |
| 2026-06-11 | Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
10,000 |
| 2026-06-11 | Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
Convert↑
|
Common Stock
|
10,000 |
| 2026-06-09 | HEWSON MARILLYN A |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
214 |
| 2026-06-09 | Pinto Daniel E |
President & COO |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
134 |
| 2026-06-09 | Woods Eugene A. |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
161 |
| 2026-05-01 | REED JOHN C |
EVP, Innovative Medicine, R&D |
Convert↓
Filing footnotes — Restricted Share Units (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. |
Restricted Share Units
|
25,255 |
| 2026-05-01 | REED JOHN C |
EVP, Innovative Medicine, R&D |
Convert↑
Filing footnotes — Common Stock (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. |
Common Stock
|
25,255 |
| 2026-05-01 | REED JOHN C |
EVP, Innovative Medicine, R&D |
Tax↓
Filing footnotes — Common Stock (Direct)
Shares withheld for payment of taxes upon vesting of RSUs. |
Common Stock
|
11,002 |
| 2026-04-23 | Joly Hubert |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
975 |
| 2026-04-23 | Doudna Jennifer A |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
975 |
| 2026-04-23 | Beckerle Mary C |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
975 |
| 2026-04-23 | McClellan Mark B. |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
975 |
| 2026-04-23 | Pinto Daniel E |
President & COO |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
1,712 |
| 2026-04-23 | MORIKIS JOHN G |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). |
Deferred Share Units
|
1,540 |
| 2026-04-23 | WEINBERGER MARK A |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
975 |
| 2026-04-23 | West Nadja |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
975 |
| 2026-04-23 | HEWSON MARILLYN A |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
975 |
| 2026-04-23 | Johnson Paula A |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
975 |
| 2026-04-23 | Woods Eugene A. |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
975 |
| 2026-03-10 | Pinto Daniel E |
President & COO |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
129 |
| 2026-03-10 | Woods Eugene A. |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
154 |
| 2026-03-10 | HEWSON MARILLYN A |
Director |
Award↑
Filing footnotes — Deferred Share Units (Direct)
Acquisition of DSUs for deferral of cash retainer under the Plan. Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Deferred Share Units
|
206 |
| 2026-02-27 | Decker Robert J |
VP Corporate Controller |
Convert↑
|
Common Stock
|
4,075 |
| 2026-02-27 | Decker Robert J |
VP Corporate Controller |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
4,075 |
| 2026-02-27 | Decker Robert J |
VP Corporate Controller |
Sell↓
|
Common Stock
|
4,075 |
| 2026-02-20 | Schmid Timothy |
EVP, WW Chair, MedTech |
Sell↓
|
Common Stock
|
1,322 |
| 2026-02-18 | Schmid Timothy |
EVP, WW Chair, MedTech |
Convert↑
|
Common Stock
|
13,625 |
| 2026-02-18 | Schmid Timothy |
EVP, WW Chair, MedTech |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable one day after the third anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
13,625 |
| 2026-02-18 | Schmid Timothy |
EVP, WW Chair, MedTech |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable one day after the third anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
8,998 |
| 2026-02-18 | Schmid Timothy |
EVP, WW Chair, MedTech |
Sell↓
|
Common Stock
|
8,998 |
| 2026-02-18 | Schmid Timothy |
EVP, WW Chair, MedTech |
Convert↑
|
Common Stock
|
8,998 |
| 2026-02-18 | Schmid Timothy |
EVP, WW Chair, MedTech |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades at prices ranging from $244.20 to $244.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
13,625 |
| 2026-02-17 | Wolk Joseph J |
Exec VP, CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades at prices ranging from $242.59 to $242.815. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
24,961 |
| 2026-02-17 | REED JOHN C |
EVP, Innovative Medicine, R&D |
Sell↓
|
Common Stock
|
2,283 |
| 2026-02-17 | Wolk Joseph J |
Exec VP, CFO |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable one day after the third anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
19,241 |
| 2026-02-17 | Wolk Joseph J |
Exec VP, CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades at prices ranging from $242.85 to $242.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
12,066 |
| 2026-02-17 | REED JOHN C |
EVP, Innovative Medicine, R&D |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
29,927 |
| 2026-02-17 | REED JOHN C |
EVP, Innovative Medicine, R&D |
Sell↓
|
Common Stock
|
21,721 |
| 2026-02-17 | Swanson James D. |
EVP, CIO |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vested and was exercisable on the third anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
20,521 |
| 2026-02-17 | Wolk Joseph J |
Exec VP, CFO |
Convert↑
|
Common Stock
|
33,386 |
| 2026-02-17 | Swanson James D. |
EVP, CIO |
Convert↑
|
Common Stock
|
20,521 |
| 2026-02-17 | REED JOHN C |
EVP, Innovative Medicine, R&D |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
21,721 |
| 2026-02-17 | Wolk Joseph J |
Exec VP, CFO |
Convert↓
Filing footnotes — Employee Stock Options (Right to Buy) (Direct)
Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable one day after the third anniversary of the grant date. |
Employee Stock Options (Right to Buy)
|
33,386 |
| 2026-02-17 | Swanson James D. |
EVP, CIO |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades at prices ranging from $242.69 to $242.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
20,521 |